Milestone Pharmaceuticals ( (MIST) ) has provided an update.
Milestone Pharmaceuticals has announced its financial results for the fourth quarter and full year of 2024, alongside a regulatory update. The company is currently seeking FDA approval for CARDAMYST, an etripamil nasal spray for PSVT, with a decision expected by March 27, 2025. If approved, Milestone plans to launch the product by mid-2025, supported by secured resources and royalty financing. The company has received a Notice of Allowance for a new patent, potentially extending intellectual property protection for CARDAMYST until 2042, enhancing its market position.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., listed on Nasdaq under the ticker MIST, operates in the pharmaceutical industry. The company focuses on developing and commercializing innovative cardiovascular medicines, with a primary emphasis on treating paroxysmal supraventricular tachycardia (PSVT).
YTD Price Performance: -11.06%
Average Trading Volume: 900,865
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $96.52M
See more insights into MIST stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com